Cystic Fibrosis Foundation invests in Felix Biotechnology

By The Science Advisory Board staff writers

March 7, 2022 -- Felix Biotechnology received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award. The award will bolster Felix's work on creating a novel therapy to manage chronic Pseudomonas aeruginosa lung infections.

The company said that its phage therapies are specially designed to consider and drive advantageous evolutionary outcomes of phage treatment, resulting in a more durable therapy.

The therapy is currently being evaluated in a clinical trial at Yale University. Felix's discovery and engineering technology platforms are built on technology from Yale and Lawrence Berkeley National Laboratory.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.